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Background: Pigeon circovirus (PiCV) is considered to be a viral agent central to the development of young
pigeon disease syndrome (YPDS). The Cap protein, a structural protein encoded by the cap (or C1) gene of PiCV,
has been shown to be responsible for not only capsid assembly, but also has been used as antigen for detecting
antibody when the host is infected with PiCV. The antigenic characteristics of the Cap protein potentially may allow
the development of a detection kit that could be applied to control PiCV infection. However, poor expression and
poor protein solubility have hampered the production of recombinant Cap protein in the bacteria. This study was
undertaken to develop the optimal expression of recombinant full-length Cap protein of PiCV using an E. coli
expression system.
Results: The PiCV cap gene was cloned and fused with different fusion partners including a His-tag, a GST-tag
(glutathioine-S-transferase tag) and a Trx-His-tag (thioredoxin-His tag). The resulting constructs were then expressed
after transformation into a number of different E. coli strains; these then had their protein expression evaluated. The
expression of the recombinant Cap protein in E. coli was significantly increased when Cap protein was fused with
either a GST-tag or a Trx-His tag rather than a His-tag. After various rare amino acid codons presented in the Cap
protein were optimized to give the sequence rCapopt, the expression level of the GST-rCapopt in E. coli BL21(DE3)
was further increased to a significant degree. The highest protein expression level of GST-rCapopt obtained was
394.27 ± 26.1 mg/L per liter using the E. coli strain BL21(DE3)-pLysS. Moreover, approximately 74.5% of the expressed
GST-rCapopt was in soluble form, which is higher than the soluble Trx-His-rCapopt expressed using the BL21(DE3)-pLysS
strain. After purification using a GST affinity column combined with ion-exchange chromatography, the purified
recombinant GST-rCapopt protein was found to have good antigenic activity when tested against PiCV-infected
pigeon sera.
Conclusions: These findings shows that the E. coli-expressed full-length PiCV Cap protein has great potential in
terms of large-scaled production and this should allow in the future the development of a serodiagnostic kit that
is able to clinically detect PiCV infection in pigeons.* Correspondence: TCTZEN@dragon.nchu.edu.tw;
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Pigeon circovirus (PiCV), is a non-enveloped virus and
is considered to be the viral agent central to the develop-
ment of young pigeon disease syndrome (YPDS). YPDS
syndrome is a multifactorial disease that includes various
unspecific clinical signs such as poor racing performance,
weight loss, lethargy, anorexia, respiratory distress and
diarrhea [1]. At present, PiCV is classified as a tentative
member of circovirus family based on its particle size, its
associated histopathology and the fact that it shares
low-level DNA homology with psittacine beak and feather
disease virus (BFDV) [2]. According to the previous re-
ports on the genomic characterization of PiCV, PiCV
has been characterized as having an ambisense single-
stranded DNA genome of about 2.0 kb [3,4]. There are
five open reading frames (ORFs) present on the ss-DNA;
V1, C2, C3 and C4; these partially overlap within the PiCV
genome. ORF C1 encodes a 30 kDa protein, which is the
putative major component responsible for assembly of the
viral capsid protein (Cap) [3]. ORF V1 encodes a non-
structural protein with putative replication-associated pro-
tein (Rep) activity [4]. The ORFs C2, C3 and C4 encodes
hypothetical proteins, the biological functions of which
remain unclear. To date, some conventional methods have
been used to detect the PiCV infection. These include
electron microscopy, histological observation and molecu-
lar diagnosis including polymerase chain reaction (PCR),
in situ hybridization and nucleic acid-based dot blot
hybridization [5-10]. Enzyme-linked immunosorbent assay
(ELISA) is a convenient and popular assay for diagnosis of
virus infections and allows the investigator to target virus-
specific antibodies in the sera of the host. Nevertheless,
very few ELISA assay systems for detecting PiCV infection
have been established successfully. Development of an
ELISA system relies on the availability of viral antigens
that are then used as ELISA coating antigen or for anti-
body production. However, the propagation of PiCV in
cell culture has never been described, and harvesting viral
antigen from pigeons is a tedious, ineffective and time-
consuming process that results in a low yield. Thus, using
a recombinant DNA method to express a PiCV viral anti-
gen has been suggested to be a better strategy for the
development of an ELISA assay system. In previously
reports, only two expression systems have been used to
produce PiCV Cap protein; these were a E. coli expression
system and a baculovirus-insect cell expression system
[11,12]. However, the production of the recombinant full-
length Cap protein was found to be hampered in E. coli
due to a failure to express the first 39 amino acid residues
at the N-terminus of the Cap protein, the coding sequence
of which includes a significant number of codons that are
rarely used in E. coli. Moreover, in above system, most of
the expressed recombinant Cap protein was found to be
in the form of inclusion bodies [11]. The informationavailable on the baculovirus-insect cell expression system
for Cap protein expression in Sf9 does not provide in-
formation on productivity on a large scale that would
allow further evaluation. In the above context, the E.
coli expression system is still easier to carry out and is
more cost-effective when applied to viral antigen produc-
tion than the baculovirus-insect cell system, although the
E. coli system does have some limitations.
To develop the Cap protein as coating antigen of an
ELISA system, the above mentioned limitations associ-
ated with using an E. coli expression system need to be
overcome; these include making sure that the full-length
of the Cap protein is expressed in E. coli and using an
expression system in which the majority of Cap protein
is produced in a soluble form rather than as inclusion
bodies. If successful, this would not only allow the efficient
purification of capsid protein on a scale that would allow
an investigation of PiCV structural biology but also the
purified recombinant protein would be potentially useful
when developing diagnostic kits for the clinical detection
of PiCV infection.
In this study, the PiCV cap gene was fused to a series
of different fusion tags in order to improve recombinant
Cap (rCap) protein expression. The rCap was then
expressed attached to three different expression tags in
order to evaluate rCap fusion protein expression and
production across a number of different E. coli strains.
Three expression vectors were used, one harboring a
glutathione-S-transferase (GST) tag, another harboring
a 6xHis tag and finally, a third harboring a thioredoxin-
6xHis (Trx-His); these were investigated to explore the
effect of these very different fusion tags on the expression
of rCap protein across various E. coli strains. In addition,
optimizations of codon usage for various amino acids
within the Cap gene were also carried out to give the
rCapopt sequence and then the effect of these changes
on expression of rCapopt in the various E. coli strains was
assessed. Finally, purified rCapopt protein was examined in
order to determine its antigenicity and therefore its useful-
ness in further serodiagnostic applications. To the best of
our knowledge, the yield of E. coli expressed full-length
rCapopt in this study after codon optimization of the cap
gene is the highest known to date.
Results
The fusion tags and the strain preference falicitates the
expression level of recombinant PiCV capsid protein in
E. coli
The various fusion tags and the various E. coli strains
had a range of effects on the expression level of the two
recombinant PiCV capsid proteins in E. coli allowing
optimization of the protein purification protocol. To
investigate the expression of PiCV capsid protein (Cap)
using the prokaryotic expression system, the cap gene
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sequences, His-tag (6xHis), glutathione-s-transferase tag
(GST) and thioredoxin-His (Trx-His) in three distinct ex-
pression vectors (Figure 1A, a, c and e). All above fusion
tags were fused with recombinant rCap at its N-terminus.
The resultant constructs, pHis-Cap, pGST-Cap and pTrx-
His-Cap were then individually transformed into three
distinct E. coli strains in order to address the effect of the
fusion tags on the protein expression levels of the cap
gene.
As illustrated in Figure 2, when E. coli BL21(DE3)
harboring pHis-Cap, pGST-Cap and pTrx-His-Cap
were examined, there was no significant amount of rCap
fusion protein present in the whole cell lysates after IPTG
induction for 4 hrs (SDS-PAGE and Western-blotting of
Figure 2A, lane 1–2; Figure 2B, lane 1–2; Figure 2C, lane
1–2, respectively). ). Proteins at the predicted molecular
weights, 32 kDa His-rCap, 58 kDa GST-rCap and 48 kDa
Trx-His-rCap, were not detected using anti-His mono-
clonal antibody and anti-GST antibody as appropriate
(Figure 2A, lane 1–2; Figure 2B, lane 1–2; Figure 2C,
lane 1–2 of Western blot).
As a result of the above findings, expression of the
PiCV rCap fusion protein in E. coli was carried out in
two other E. coli strains, BL21(DE3)-pLysS and BL21
(DE3)-RIPL and their protein expression levels compared
to that of E. coli BL21(DE3). The expression patterns of
the rCap fusion protein in E. coli BL21(DE3)-pLysS and in
E. coli BL21(DE3)-RIPL containing pHis-Cap, pGST-Cap,
and pTrx-His-Cap are shown in Figures 2A, B, C, respect-
ively,. The expression patterns for the rCap fusion protein
were relatively poor in BL21(DE3)-pLysS. No matter
whether the His-rCap or GST-rCap protein was being
expressed, the protein products were almost undetect-
able. In contrast, the 48 kDa specific protein band for
Trx-His-rCap could be detected using anti-His monoclo-
nal antibody when the BL21(DE3)pLysS strain containing
pTrx-His-Cap was induced with IPTG (Figure 2C, lane
3–4 of SDS-PAGE and Western blot). In addition, when
pGST-Cap and pTrx-His-Cap were transformed into
BL21(DE3)-RIPL strain, the GST-rCap and Trx-His-rCap
protein could be successfully expressed and detected by
both SDS-PAGE and Western-blot analysis (Figure 2B,
lane 5–6; Figure 2C, lane 5–6 of SDS-PAGE and Western
blot). Overall, expression level of the Trx-His-rCap pro-
tein, was significant higher than that of the GST-rCap
protein in BL21(DE3)-RIPL strain. However, in the BL21
(DE3)-RIPL strain containing the pHis-Cap plasmid, ex-
pression of His-rCap was still almost undetectable after
IPTG induction (Figure 2A, lane 5–6 of SDS-PAGE and
Western-blot, respectively). Thus the fusion tags GST and
Trx-His seem to be able to facilitate expression of PiCV
rCap protein in E. coli and, moreover, the E. coli strain
used also plays a crucial role in expression and seems toaffect the further application of these strains in large-scale
production.
Optimization of the codon usage of the cap gene enhances
of recombinant PiCV capsid protein expression in E. coli
Based on the results shown in Figure 2A, B and C, the
expression levels of rCap were improved in E. coil when
a Trx-His tag or GST tag on the N-terminus of rCap
protein was used. The best expression was obtained
using the strain BL21(DE3)-RIPL, which harbors extra
copies of tRNAargU, proL, ileY, leuW. This is commercial E.
coli host strain used for the gene expression of recom-
binant proteins that contain E. coli’s rare codons. The
expression of Trx-His-rCap protein in strain BL21(DE3)-
RIPL showing an expression level was significant higher
than when the BL21(DE3) and BL21(DE3)-pLysS strains
were used (Figure 2B, lane 5–6; Figure 2C, lane 5–6), this
suggested that optimization of the codon usage in the
rCap protein might further improve the expression level
of rCap.
As illustrated in Figure 1B, the cap gene does contain
a number of E. coli’s rare codons, which were detected
when the sequence was examined by the GeneScript rare
codon analysis tool (http://www.genscript.com/cgi-bin/
tools/rare_codon_analysis). Approximately 18% rare E.
coli codons are presented in PiCV cap gene, and most of
rare codons are basic amino acid residues, such as lysine
(K) and arginine (R) and are presented near the 5’-end of
the cap gene. Using GeneOptimizer software, the codons
of the cap gene were optimized without altering the amino
acid sequence of the protein to give a gene sequence that
had the preferred codon usage of E. coli. As illustrated in
Figure 1B, this 819 bp DNA fragment was named as
Capopt. Three recombinant constructs were then created
using the codon optimized cap gene sequence and then
transformed into E. coli to explore expression levels
(Figure 1A, panel b, d and f ). As shown as Figure 2A,
2B and C, using SDS-PAGE and Western-blot analysis,
when E. coli BL21(DE3) or E. coli BL21(DE3)-pLysS
were used as host to express the His-rCapopt or the
GST-rCap protein, the expression proteins were almost
undetectable after IPTG induction (Figure 2A, panel 7–8
for BL21(DE3) and panel 9–10 for BL21(DE3)-pLysS).
However, when the recombinant E. coli BL21(DE3) and
BL21(DE3)-pLysS strains harbored the pGST-rCapopt
plasmid, rCapopt protein was produced at significant
levels after IPTG induction (Figure 2B, panel 7–8 for
BL21(DE3) and panel 9–10 for BL21(DE3)-pLysS to
SDS-PAGE and Western-blot, respectively). The quan-
titative yield for GST-rCapopt protein production using
the BL21(DE3)-pLysS strain was 394.2 ± 26.1 µg/ml,
which is higher than that of the GST-rCap protein at
119.2 ± 17.0 µg/ml when the latter protein is expressed
in the BL21(DE3)-RIPL strain (right panel of Figure 3A
Figure 1 A schematic diagram of the constructions used in this study and the alignment results for the expressed PiCV capsid gene.
(A) The full-length wild-type and codon-optimized PiCV capsid protein genes were cloned independently into three expression vectors pET28a,
pGEX-4T-1 or pET32a. The PiCV capsid protein with the various different fusion tags, namely a six-histidine (6xHis), a Glutathione-S-transferase
(GST) and a Thioredoxin-coupled six-histidine (Trx) at its N-terminus were expressed by T7 or Tac promoter-driving after IPTG induction. (B) The
nucleotide sequences were compared between the wild-type (WT) and the codon-optimized (OPT) PiCV capsid protein genes. The asterisk (*)
represents the fact that the aligned nucleotides are identical.
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GST-rCapopt protein in BL21(DE3)-pLysS was even
higher than that of BL21(DE3) (Figure 2B, panel 7–10
to SDS-PAGE and Western-blot, respectively). This
yield of GST-rCapopt protein in the BL21(DE3)-pLysS
was 1.3 fold higher than that of the GST-rCapopt pro-
tein expressed in the BL21(DE3) strain (right panel of
Figure 3A). Furthermore, the pTrx-His-rCopt plasmid
in the BL21(DE3) and BL21(DE3)-pLysS strains also
produced a very similar pattern to that of the different
E. coli strains expressing GST-rCapopt protein (Figure 2C,
panel 7–8 for BL21(DE3) and panel 9–10 for BL21(DE3)-
pLysS to SDS-PAGE and Western-blot, respectively).
Furthermore, the quantitative yield for the Trx-His-
rCapopt protein in the BL21(DE3)-pLysS strain after IPTGinduction for 4 h reached 544.5 ± 33.2 µg/ml at the same
optical density (OD) as the cultures, which represents
a 5.07 fold increase over Trx-His-rCap in BL21(DE3)-
pLysS by densitometric analysis (Figure 2C, panel 3–4
for Trx-His-rCap and panel 9–10 for Trx-His-rCapopt;
right panel of Figure 3B). In addition, the yield of Trx-
His-rCapopt protein in BL21(DE3)-pLysS was higher
than that of Trx-His-rCapopt protein at 283.3 ± 9.0 µg/ml
using BL21(DE3) strain and IPTG induction (right panel
of Figure 3C). These findings confirm that the codon-
optimized of the cap gene was able to improve protein
expression significantly and allowed large amounts of
intact rCapopt protein to be produced in E. coli BL21
(DE3) or in BL21(DE3)pLysS with either the GST or
the Trx-His fusion tag.
Figure 2 Effect of fusion tags, E. coli strains and rare codon replacement on recombinant PiCV capsid protein expression. The three expression
plasmids containing wild-type PiCV capsid gene were expressed in E. coli strains BL21 (DE3), BL21 (DE3)-pLysS and BL21 (DE3)-CodonPlus-RIPL. Furthermore,
similar plasmids but containing the codon-optimized PiCV capsid gene were also expressed in BL21 (DE3) and BL21 (DE3)-pLysS. All examined
recombinant PiCV capsid proteins were analyzed by SDS-PAGE and Western-blotting. Anti-6xHis tag monoclonal antibody was used to recognize the
6xHis-tagged (A) and Trx-tagged (C) Cap proteins. Anti-GST monoclonal antibody was used for detecting GST-tagged (B) Cap proteins. Lane M,
pre-stained protein marker; lane 1, 3, 5, 7 and 9, before IPTG induction; lane 2, 4, 6, 8 and 10, after IPTG induction for 4 hrs cultivation. The solid triangle
pinpoints the expressed Cap protein.
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capsid protein
To further characterize and purify the rCapopt protein,
the solubility of expressed two rCapopt fusion proteins,
GST-rCapopt and Trx-His-rCapopt was explored. E. coli
BL21(DE3)pLysS cells over-expressing either GST-rCapopt
or Trx-His-rCapopt was separated into the supernatant
and pellet fractions after sonication of a suspension ofharvested cells. The analysis by SDS-PAGE demonstrated
that both GST-rCapopt and Trx-His-rCapopt protein
existed in soluble and insoluble forms (Figure 4A). By
densitometric analysis, the solubility of GST-rCapopt and
Trx-His-rCapopt protein were determined (Figure 4B).
Approximately 74.58% of the GST-rCapopt was soluble,
which is higher than the 67.45% solubility obtained for
Trx-His-rCapopt protein when BL21(DE3)pLysS cells were
Figure 3 Growth kinetics and production profiles of recombinant PiCV capsid protein (Cap) in different E. coli strains. (A) The growth
and protein production profiles of the three recombinant E. coli strains expressing either the GST-Cap or GST-Capopt protein. Two strains, BL21
(DE3) and BL21 (DE3)-pLysS expressing GST-Capopt, and one GST-Cap expressing strain BL21 (DE3)-CodonPlus-RIPL were used in this study
post-induction. (B) Growth and protein production profiles of four recombinant E. coli strains expressing Trx-His-Cap or Trx-His-Capopt protein.
Two E. coli strains, BL21 (DE3) and BL21 (DE3)-pLysS were used to express Trx-His-Capopt, and other two recombinant E. coli strains, BL21
(DE3)-CodonPlus-RIPL and BL21 (DE3)-pLysS were used to express Trx-His-Cap. Similar tests to those described above were used to detect the
time course of protein expression after IPTG induction.
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rCapopt protein was then carried using a GST affinity col-
umn. After affinity chromatography combined with on-
column cleavage by thrombin, the presence of collected sol-
uble rCap protein was clearly detectable by SDS-PAGE ana-
lysis (Figure 5A, lane 4). The specific 30 kDa band obtained
from the column was approximately 90% pure (Figure 5A,
lane 4), which indicates that rCap protein had been success-
ful cleaved from GST fusion tag. To further improve the pur-
ity of the rCap, the GST-column purified rCap was subjected
to cation exchange chromatography. As shown in Figure 5B,
the purity of rCap was significantly increased by this process.
Once the purification process had been completed,
only cleaved GST fusion protein was present at almosthomogeneity (Figure 5A, lane 7). When the chromatographic
purified rCap protein was examined by MALDI-TOF, five
peptides from rCap protein were identified after trypsin di-
gestion and these demonstrated good alignment and a high
score when compared to the predicted protein (Figure 5C).
The longest peptide fragment, PLGVDITTWKGFGHTVP
MYDAR consisted of 22 amino acid residues and, overall,
the coverage was 27% of the published amino acid
sequence of the PiCV Cap protein (Accession No.
AER38484) without any miss-match (Figure 5C). These
MALDI-TOF results confirmed that the purified 30 kDa
protein is PiCV Cap protein and that the optimization of
E. coli’s preferred codon usage within the cap gene had
not altered the amino acid sequence (Figure 5C).
Figure 4 The solubility of recombinant GST-Capopt and
Trx-His-Capopt protein. The two proteins were expressed
by E. coli strain BL21 (DE3)-pLysS transformed pGST-Capopt and
pTrx-His-Capopt respectively. SDS-PAGE (A) was used to analyze the
protein distribution pattern of suspension fraction and the pellet
fraction. The soluble percent of two recombinant proteins was
determined by measuring the intensity of target protein bands on
coomassie blue-strained gels (B). Lane M, pre-stained protein
marker; lane I, total protein-expressed cell lysate; lane S, suspension
fraction from centrifugal protein-expressed cell lysate; lane P, pellet
fraction from centrifugal protein-expressed cell lysate. The solid
triangle pinpoints the expressed Capopt protein.
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sero-diagnosis
Next we investigated whether the PiCV rCap protein
expressed by E. coli has antigenic activity when against
to PiCV-infected pigeon serum. As illustrated in Figure 6,
Western blot analysis using PiCV-infected pigeon serum
from five PiCV-infected pigeon showed that the E. coli
expressed PiCV rCap proteins had the correct antigenic
characteristics in terms of the detection of a specific
band of approximately 30 kDa (Figure 6, lane 1–5). In
contrast, when PiCV-noninfected serum was used, there
were no any corresponding bands present on the PVDF
membrane (Figure 6, lane 6). These findings supports E.coli expressed PiCV rCapopt protein as retaining the
protein’s original antigenic activity when used against
PiCV-infected pigeon serum.
Discussion
PiCV infection is associated with development of young
pigeon disease syndrome (YPDS). At present, no vaccine
is available to prevent PiCV infection. Among circovirus,
capsid proteins have been investigated as to their usefulness
as immunogens for developing subunit vaccines [13-15].
The Cap protein is the only capsid protein encoded by
PiCV. Generally speaking, PiCV Cap protein is thought to
be a promising target for the production of a recombinant
vaccine or the development of a sero-diagnostic kit [11,12].
Recently, a truncated form of PiCV Cap protein has been
shown to have been successful expressed in E. coli [11].
However, expression of full-length recombinant PiCV Cap
protein using an E. coli system has remained very difficult.
E. coli remains the most attractive expression system
when assessing the expression of a heterologous protein for
many different purposes [16]. Using an E. coli expression
system to express a heterologous recombinant protein has
several advantages; these include cost-effectiveness, ease
of production, time-saving and others. In this study,
we have successfully produced for the first time the
full-length Cap protein of PiCV using an E. coli expres-
sion system Previously, it has been suggested that the
Cap protein is likely to be the sole structural protein of
PiCV and this protein thus controls viral capsid assembly.
Thus, have purified full-length Cap protein will help with
the detailed study of PiCV's structure biology and it will
also help with PiCV vaccine development and the produc-
tion of a serodiagnostic kit for PiCV detection. The PiCV
Cap protein has been demonstrated to have antigenic
activity and to be able to recognize by PiCV specific
antibodies [11,12]. However, up to the present, a lack of
highly purified full-length Cap protein has hindered re-
search in these areas. The main problem with the E. coli
approach to producing PiCV Cap protein has been poor
protein expression and low protein solubility. Previous
studies have shown that the production of recombinant
Cap protein using an E. coli expression is relatively diffi-
cult and therefore this has become a bottle-neck [11].
This study surmounts this problem and will allow the
efficient production of recombinant PiCV Cap protein
for future investigations.
A number of different strategies are available when
improving protein expression and enhancing the protein
solubility in E. coli. These factors include cultivation
parameters, the fusing of an affinity tag of one type or
another to the target protein and the optimization for
E. coli of the codon usage of the foreign gene. [13,17,18].
This study explored how three different fusion tags, GST,
His-tag and Trx-His tag, affected Cap protein expression;
Figure 5 Purification of recombinant PiCV-Capopt protein using on-column cleavage by thrombin and SP cation exchange chromatography.
(A) The GST tag of recombinant GST-PiCV-Capopt protein was removed by the on-column cleavage method as described in Material and Method and the
residue rCapopt were eluted and collected for the next purified procedure. The results of the purification were examined by SDS-PAGE. Lane M, pre-stained
protein marker; lane 1, total protein-expressed cell lysate; lane 2, flow-through, lane 3, GST affinity column washing; lane 4, Tag-free rCapopt elute collected
after on-column cleavage; lane 5, first column washing after on-column cleavage; lane 6, second column washing after on-column cleavage; lane 7 GST
tag elute after on-column cleavage. (B) The rCapopt eluted protein was further purified by SP cation exchange chromatography and the purification result
assessed by SDS-PAGE. Lane M, pre-strained protein marker; lane 1, Input fraction of rCapopt elute collected from a previous on-column cleavage purified
step; lane 2 flow-through; lane 3, SP cation exchange column washing; lane 4, eluted fraction of purified rCapopt. (C) Identity of the rCapopt protein
was determined by MALDI-TOF. The red-labeled marker represents actual amino acid matches and there is 27% protein sequence coverage.
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provement in the future. Both a GST and a Trx-His fusion
tag was found to significantly improve the yield of rCap
protein compared to a 6 ×His tag (Figure 2A, B and C). In
a previous study, Liu et al. described how the expression
of the Cap protein of porcine circovirus (PCV) was suc-
cessfully improved in E. coli by fusing the maltose-binding
protein (MBP) to the target protein [19], but the mech-
anism by which a fused MBP-8xHis tag is able to improve
protein expression remains unclear. Nonetheless, one
possibility is that protein solubility was improved [19].
Similarly, in our previous study, the addition of a GST
tag to the CAV VP1 protein also improved expression
in E. coli significantly compared to a His × 6 tag [13].
Thus some fusion tags would seem to be able to help
improve the solubility of E. coli expressed proteins more
than other tags; this occurs perhaps by promoting the
correct folding of their selected fusion partner [13,19].
Like porcine circovirus (PCV), beak and feather disease
virus (BFDV) and chicken anemia virus (CAV), PiCV is
also rich in basic amino acid residues close to the N-terminus of the capsid protein. This region has been pre-
dicted to be a nuclear localizing sequence and a nucleic
acid binding domain via the DNAbinder software package
(http://www.imtech.res.in/raghava/dnabinder/submit.html).
In previous studies, this N-terminal regions of capsid
proteins have often caused problems with recombinant
protein expression using a prokaryotic system [11,13,20].
Deletion of the N-terminus of the capsid protein can often
overcome this problem allowing the protein to be expressed
successfully in E. coli; nonetheless, the usefulness of the
truncated protein for diagnosis or for the development of
a subunit vaccine is likely to be hampered. Obviously only
the intact capsid protein contains all of the epitopes for
elicitation of virus neutralizing antibodies by the host.
Thus, it is best to express full-length PiCV capsid protein
rather than a truncated form when developing a vaccine
or a diagnostic kit.
The present study found that the E. coli strain BL21
(DE3)-RIPL, when used to express Trx-His-rCap, gave
the highest level of protein expression, significantly
higher than any other combination (Figure 2B, lane 5–6;
Figure 6 Antigenicity characterization of the purified
recombinant Capopt protein by Western blot analysis using
PiCV-positive sera. Lane M, pre-stained protein marker; lane 1 to
lane 5, PiCV-positive sera were used in Western blotting and the
recognized position of rCapopt protein is indicated by a solid
triangle. The pigeons that had PiCV-positive sera were identified as
virus-positive animals using a PCR detection methods as described
in a previous study [6]. Lane 6, Pigeon normal serum was used
as control.
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ies of tRNAargU, proL, ileY, leuW are able to improve PiCV
Cap protein expression usefully. In addition, it confirms
that the E. coli rare codons with the cap gene have a sig-
nificant effect on its expression. Using the GeneScript
rare codon analysis tool, it was found that approximately
18% of the codons in the PiCV cap gene are rare E. coli
codons. It had been suggested than when a target gene
contains >10% rare cordons of E. coli, protein expression
efficiency is likely to be decreased [21]. Rosenberg et al.
also described how the efficiency of protein translation
might be affected by an abundance of rare codons near
the 5’-end of the gene. Thus, when a codon-optimized
cap gene was used, rCapopt, rather than rCap, expression
of the Cap protein was significantly enhanced in E. coli
compared to supplying extra copies of the rare tRNA
genes via the expression strain.
We also investigated which of two different recombin-
ant E. coli strains, BL21(DE3) and BL21(DE3)pLysS, was
able to improve protein production and yield. With both
GST-Capopt and Trx-His-Capopt, expression was better
with BL21(DE3) and produced more Cap protein than
BL21(DE3)-RIPL (right panel of Figure 3A and 3B). It is
worth noted that BL21(DE3)pLysS has a higher growth
rate than BL21(DE3) or BL21(DE3)-RIPL when expressingTrx-His-Capopt or Trx-His-Cap. (left panel of Figure 3B).
This discrepancy may involve either higher protein stabil-
ity or Trx-His-Capopt having a less cytotoxic nature when
present in BL21(DE3)pLysS. However, these effect were
not present during the production of GST-Capopt protein
using E. coli BL21(DE3)pLysS at high expression levels.
The superiority of Trx-His-Capopt expression in BL21
(DE3)pLysS may be due to the presence in the strain of
the pLysS plasmid during protein induction. The cytotox-
icity tolerance of BL21(DE3)pLysS might be associated
with the expression of T7 lysozyme which attenuates
transcription leakage by T7 RNA polymerase. However,
this phenomenon was not significant when GST-Capopt
was expressed grown using BL21(DE3)pLysS. GST-Capopt
was decreased when there was induction by IPTG. One
possibility is that the cytotoxicity of GST-Capopt may be
higher that that of Trx-His-Capopt in BL21(DE3)pLysS.
In other words, a “protein burden” may not yet have
been encountered when BL21(DE3)pLysS was used to
express Trx-His-Capopt. Overall, we concluded that
BL21(DE3)pLysS is the preferred choice for expressing
Trx-His-Capopt.
The solubility of recombinant Cap protein is a potential
problem and in this context the solubility of GST-Capopt
protein is superior to that of Trx-His-Capopt. Further-
more, it is very easy to apply the protein to a GST-affinity
column in order to carry out a protein purification. More-
over, the Cap protein contains basic amino acid residues
rich at its N-terminus. Such highly positive charge amino
acids within the recombinant Cap protein allow easy pol-
ishing by cation exchange column as part of down-stream
processing. Therefore, it seems likely that, a higher purity
of Cap protein can be obtained when an affinity column is
combined with an ion-exchange chromatography during
vaccine development.
In this study, positive PiCV-infected pigeon sera were
used to evaluate the antigenic activity of the E. coli-
expressed recombinant PiCV Cap protein. All tested
PiCV-infected pigeon sera were able to demonstrate
that E. coli-expressed recombinant PiCV Cap protein
has the correct antigenic activities. This might be a result
of the E. coli-expressed recombinant Cap protein display-
ing all of the appropriate protein antigenic regions on the
protein surface for recognition by the pigeons' antibodies.
However, rCap protein when used against some pigeon
sera did not show very strong antigenicity. This perhaps
suggests that the titers of antibodies against PiCV Cap
protein have various levels in pigeons and such variation
might explain in lower performance of antigenicity in cer-
tain birds.
Conclusions
In conclusion, using a prokaryotic system, the optimal
expression of recombinant full-length PiCV Cap protein
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more, by fusing the Cap protein to an affinity tag, by
using the appropriate preferred E. coli and by optimizing
the codon usage of the polypeptide, it was possible to
increase the yield of Cap fusion protein significantly. In
this context, a convenient and cost-effective strategy for
increasing the expression of Cap protein, which was
used herein, was the direct engineering of the codons of
the Cap protein to fit the E. coli codon preferences.
This approach paves the way for the large-scale efficient
production of the PiCV Cap protein. In the future, this
will also allow recombinant Cap protein to be used as a
potential antigen for the development of a PiCV diagnos-
tic test.Methods
Bacterial strains and cell inoculation
Three commercial E. coli strains, BL21(DE3) (Invitrogen,
Carlsbad, CA), BL21(DE3)CodonPlus-RIPL (Stratagene,
La Jolla, CA) and BL21(DE3)pLysS (Stratagene, La Jolla,
CA) were used and maintained at 37°C in the Luria-Bertani
(LB) medium (1% tryptone, 0.5% yeast extract, 1% NaCl,
pH 7.0). First, 0.5 mL of an overnight culture was inocu-
lated into 50 mL LB medium to allow strain activation
by growth at 37°C for around 3 hours, by which time
the optical density of culture had reach 0.5 of OD600.
These bacterial cells were then used for transformation.Construction of the recombinant plasmids
A 822 bp of cDNA fragment consisting of the cap gene
that encodes the full-length PiCV capsid protein was
synthesized by Genemark Biosci & Tech Co. (Taichung,
Taiwan) based on the published sequence (Columbid
circovirus, isolate 9030; Accession No. AJ298229). This
cDNA was cloned into either pET28a, pET32a (Novagen,
Madison, WI) or pGEX-4T-1 (GE Healthcare, Piscataway,
NJ) individually using EcoR1 and XhoI (Takara, Japan)
restriction sites. The resulting recombinant plasmids were
designated pHis-Cap, pTrx-His-Cap and pGST-Cap, re-
spectively (Figure 1, panel a, e and c). To improve the
codon usage of the cap gene from PiCV, a second cDNA
sequence was synthesized by Genemark Biosci & Tech Co
that contained the codons that were optimized for E. coli;
this was also ligated individually into the same three E. coli
expression vectors using the same restriction sites; these
constructs were designated pHis-Capopt, pTrx-His-Capopt
and pGST-Capopt, respectively (Figure 1, panel b, f and d).
The six constructs were then individually transformed into
One Shot® Top10 (Invitrogen, CA) chemically competent
E. coli for maintenance of the recombinant plasmids.
Transformants that containing a insert of the correct size
were then confirmed as correct by restriction enzyme di-
gestion and by DNA sequence analysis.Expression of recombinant Cap protein (rCap) and codon
optimized Cap protein (rCapopt) in E. coli
To express the recombinant rCap or rCapopt protein, all
the constructed recombinant plasmids carrying either the
cap gene or the codon-optimized cap gene, as described
in Figure 1, were transformed into various E. coli strains
to allow evaluation of protein expression. Three commer-
cial E. coli host strains, BL21(DE3), BL21(DE3)CodonPlus-
RIPL and BL21 (DE3)pLysS, each with a different recom-
binant construction, were used for protein induction and
expression. The culture conditions, the composition of the
LB medium and the protein induction condition of these
recombinant strains have been described previously [13].
After IPTG induction, samples of the cells were harvested
and analyzed for protein expression. The total protein
was measured by the procedure described in a previous
study [22]. Samples containing the expressed Cap or
Capopt proteins were analyzed by 12.5% SDS-PAGE and
Western-blotting using a monoclonal anti-His antibody
(Invitrogen, Carlsbad, CA) or a monoclonal anti-GST anti-
body (GE healthcare, Piscataway, NJ).
Purification of recombinant Capopt protein using GST
affinity chromatography with on-column cleavage by
thrombin
Recombinant rCapopt protein was purified from cells
expressing the GST-rCapopt protein. This was carried
out by spinning down 50 mL of culture supernatant
and resuspended the pellet in GST resin binding buffer
(140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM
KH2PO4, pH 7.3). The mixture was then sonicated on ice
three times for 3 minutes using a 20% pulsed activity cycle
(MISONIX Sonicator® 300). Next, the lysate was centri-
fuged for 10 min at 10,000 rpm to remove the cell debris.
The resulting cell supernatant was loaded onto a GSTrap
FF affinity column (GE healthcare, Piscataway, NJ) for
protein purification using the standard procedure de-
scribed in a previous study [13]. The total protein con-
centration of each collected fraction from the column
was determined using a Micro BCA kit (Pierce, Rockford,
IL) with bovine serum albumin acting as the reference
protein. The purity of the protein from each fraction was
analyzed by 12.5% SDS-PAGE and then the resulting gels
were Western blotted using monoclonal anti-GST anti-
body (GE Healthcare, Piscataway, NJ).
Mass spectrometry
To confirm the identity of the recombinant Capopt
protein, E. coli expressed GST-rCapopt protein that had
been purified by GSTrap FF column was used. The
rCapopt protein that had been eluted from the GSTrap
FF column was loaded onto a SP cation exchange chroma-
tography column (GE Healthcare) for further purification.
The cation exchange column-purified rCapopt protein
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band was then cut out from the 12.5% SDS-PAGE gel
after coomassie blue staining and digested with trypsin.
The resulting peptides were subjected to the MALDI-
TOF-MS mass spectrometry (ESI-QUAD-TOF) to allow
amino acid sequence identification of the protein, as
described in a previous study [22].
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